MidCap Financial Investment Corporation

Good morning and welcome to the earnings conference call for the period ending June 30th, 2025 for MidCap Financial Investment Corporation. At this time, all participants have been placed in a listen-only mode. The call will be open for a question-answer session following the speaker's prepared remarks. If you would like to ask a question at that time, simply press star and then 1 on your telephone keypad. If you would like to withdraw your question, press star, then 2. I will now turn the call over to Elizabeth Besson, Investor Relations Manager for MidCap Financial Investment Corp.

Thank you, Operator, and thank you, everyone, for joining us today. We appreciate your interest in MidCap Financial Investment Corporation. Speaking on today's call are Tanner Powell, Chief Executive Officer, Ted McNulty, President, and Kenny Seifert, our newly appointed Chief Financial Officer. Howard Widra, Executive Chairman, and Greg Hunt, our former CFO, who now serves as an advisor, is on the call and available for the Q&A portion of today's call. I'd like to advise everyone that today's call and webcast are being recorded. Please note that they are the property of Midcalf Financial Investment Corporation and that any unauthorized broadcast in any form is strictly prohibited. Information about the audio replay of this call is available in our press release. I'd also like to call your attention to the customary safe harbor disclosure in our press release regarding forward-looking information. Today's conference call and webcast may include forward-looking statements. You should refer to our most recent filings with the SEC for risks that apply to our business and that may adversely affect any forward-looking statements we make. We do not undertake to update our forward-looking statements or projections unless required by law. To obtain copies of our SEC filings, please visit either the SEC's website at www.sec.gov or our website at www.midcapfinancialic.com. I'd also like to remind everyone that we've posted a supplemental financial information package on our website, which contains information about the portfolio, as well as the company's financial performance. Throughout today's call, we will refer to MidCap Financial Investment Corporation as either MFIC or the BDC, and we will use MidCap Financial to refer to the lender headquartered in Bethesda, Maryland. At this time, I'd like to turn the call over to Tanner Powell, MFIC's Chief Executive Officer.

Thank you, Elizabeth. Good morning, everyone, and thank you for joining us for MidCap Financial Investment Corporation's second quarter earnings conference call. In case you missed our mid-June filing, we're pleased to share that Kenny Cyphers has been appointed as MFIC's new chief financial officer, which took effect as of the close of business on June 30th. Kenny has been a key leader within Apollo's finance and accounting team since 2015. Kenny previously served as the CFO of both AFT and AIF, the two funds that MFIC merged with last year. Greg Hunt, MFIC's former CFO, will continue to support the company as an advisor through the end of December to ensure a smooth and effective transition. Additionally, Howard Widra, MFIC's executive chairman, informed our board of his intention to retire from Apollo at the end of 2026. We are thankful to both Greg and Howard for their many contributions to MFIC. For today's call, I will begin by providing an overview of MFIC's second quarter results along with an update on the meaningful progress we've made reducing our investment in Merckx. I will then turn the call over to Ted, who will share our views on the current market environment, walk through our investment activity for the period, and provide an update on the portfolio. Kenny will then review our financial results and capital position. Yesterday, after market closed, we reported results for the second quarter. Net investment income, or NII per share, was $0.39 for the June quarter. which corresponds to an annualized return on equity or ROE of 10.5%. Gap net income per share was 19 cents for the quarter, which corresponds to an annualized ROE of 5.2%. NAV per share was $14.75 at the end of June, down 1.2% compared to the prior quarter. The decline in NAV per share was primarily due to a handful of positions that are experiencing company-specific challenges, partially offset by a gain on Merckx, which we will touch on shortly, and NII, slightly exceeding the dividend. During the June quarter, MFIC made $262 million of new commitments across 29 transactions. MidCap's strong incumbent position continues to be a competitive advantage, as evidenced by the fact that slightly more than half of the 29 commitments were made to existing portfolio companies. This underscores the power of incumbency, particularly in a muted M&A environment. We also observed a slight increase in the spread per unit of leverage on new commitments compared to the prior quarter, which Ted will discuss later. Moving on to Merck's, our aircraft leasing portfolio company, which as you know, we have been actively working to reduce. During the June quarter, Merck sold one aircraft, which resulted in $8.5 million pay down to MFIC. We're very pleased to share several recent positive developments related to our investment in Merck's that occurred subsequent to quarter end. As mentioned on last quarter's call, we were working on multiple sales campaigns and anticipated MFIC's exposure to Merck's to decline in the coming quarters. We are happy to report that we've made significant progress toward this objective. Post-quarter end, Merck successfully completed a sales transaction covering the majority of its aircraft. Given the strong market environment, we were able to sell these aircraft above the value vetted in Merck's valuation, which resulted in a modest write-up on our investment during the June quarter. In addition, in July, Merck's received payments from insurers related to the three aircraft detained in Russia – in the amount of $30.9 million, which brings Merck's total recoveries to date to approximately $47.4 million on those three aircraft. Similar to the sales transaction, the insurance proceeds were slightly above the amounts assumed in Merck's valuation. Following the sales transaction and the insurance recoveries, Merck's will be repaying approximately $90 million to MFIC on a net basis in the September quarter, reducing MFIC's investment by nearly half. As part of the sales transaction, Merck's is also expected to receive additional consideration of approximately $30 million anticipated by year-end 2025 or early 2026. Both the insurance recoveries and the sales transaction combined are expected to result in a positive impact to NAV in the high single digit per share range relative to its June 30th, 2025 carrying value. To facilitate the Merck's sales transaction, MFIC temporarily provided additional capital to Merck's. As a result, MFIC has incurred incremental interest expense associated with this temporary capital infusion in the September quarter of approximately $1 million, or one cent per share. On a pro forma basis, adjusting Merck's $185 million fair value as of the end of June for this $90 million net pay down, MFIC's investment in Merck's will total approximately $95 million, representing approximately 2.8% of the total portfolio, down from 5.6% at the end of June. Of the $90 million net repayment, approximately $25 million will be used to reduce the Merck's Revolver and the remaining $65 million applied to our equity investment in Merck's. As mentioned, MFIC will be receiving additional consideration totaling approximately $30 million by the end of 2025 or in early 2026, which will further reduce MFIC's exposure to Merck's. Let me now walk you through what remains in Merck's. MFIC's remaining investment in Merck's consists of four aircraft plus the value associated with Merck's servicing platform. As a reminder, Merck's earns income through its servicing activities for Navigator, Apollo's dedicated aircraft leasing fund. Navigator is actively pursuing the sale of its fleet. Merck's received a servicing fee. Merck's receives a servicing fee on each aircraft sale. Pro forma for the sale transaction, the servicing business represents approximately 40% of the total value. Taking a step back, this reduction in our exposure to Merck's lowers MFIC's exposure to an under-yielding asset and provides us with capital to deploy into first lien middle market loans sourced by MidCap Financial, which we believe will deliver a higher and more attractive risk-adjusted return. At the current base rates, we estimate that reinvesting $90 million, comprising of $25 million from Merck's Revolver and $65 million from equity, is expected to generate approximately $0.06 per share in additional annual net investment income, enhancing long-term value for our shareholders. The remaining value of Merck's, once realized and reinvested, will generate another approximate $0.06 per share in additional net investment income at current base rates. Turning to our dividend, on August 5th, 2025, our Board of Directors declared a quarterly dividend of 38 cents per share for shareholders of record as of September 9th, 2025, payable on September 25th, 2025. As mentioned, we intend to redeploy the capital repaid from Merck's, which should be accretive to MFIC's earnings power and strengthen our dividend coverage going forward. With that, I will now turn the call over to Ted.

Thank you, Tanner. Good morning, everyone. Beginning with the market environment, the quarter began with heightened volatility driven by the U.S. presidential administration's announcement of aggressive tariffs. This announcement temporarily disrupted activity, leading to a pause in new issuance. However, as the quarter progressed, we observed a significant improvement in market sentiment and issuance activity picked up, particularly after a pause on tariffs was announced and several trade deals were struck. Despite the turbulent start to the quarter, most major asset classes delivered positive returns. Importantly, we are beginning to see signs of a pickup in sponsor M&A activity. The U.S. economy has continued to show stability, characterized by high but gradually moderating inflation, despite the pressure from tariffs. The labor market has shown resilience, with unemployment holding steady. In response, the Federal Reserve has kept its policy rate unchanged, opting to wait for greater clarity on the economic impact of evolving trade and fiscal policies. We believe the core middle market, where we are focused, does not compete directly with either the broadly syndicated loan market or the high-yield bond market. Regardless of muted M&A activity, we see that many of our borrowers continue to have add-on financing needs, which is an important source of deal flow. Next, I'm going to spend a few minutes reviewing our second quarter investment activity and then provide some detail on our investment portfolio. As a reminder, MFIC is focused on lending to the core middle market on a first lien senior secured basis. We believe this segment of the direct lending market offers attractive risk-adjusted yields and is less competitive compared to other segments of the direct lending market. MidCap Financial's longstanding presence in the middle market and its deep network of sponsor relationships enables us to continue to see a wide range of attractive investment opportunities. As a result, we believe the risk-adjusted returns available to firms like MidCap Financial and MFIC are among the most attractive in the direct lending market across cycles. In the June quarter, we continued to deploy capital into assets with what we believe to be strong credit attributes. As mentioned, MFIC's new commitments in the June quarter totaled $262 million with a weighted average spread of 538 basis points across 29 different companies. Excluding two outliers, the weighted average spread on new commitments was 526 basis points. We also observed a slight decline in the net leverage on new commitments. The weighted average net leverage on new commitments was four times in the June quarter, down from 4.2 times in the prior quarter. Our fee structure, which is one of the lowest among listed BDCs, allows us to produce attractive ROEs at current spreads. Gross fundings, excluding revolvers, totaled $254 million. Sales and repayments, excluding revolvers and MERCs, totaled $108 million. Net revolver fundings were approximately $7 million. And, as mentioned, we received an $8.5 million pay down for MERCs. In aggregate, net fundings were $144 million. Moving to our investment portfolio, at the end of June, our portfolio had a fair value of $3.33 billion and was invested in 249 companies across 51 industries. As a reminder, in the March quarter, we transitioned our industry classification from the Moody's Industry System to Global Industry Classification System, or GICS. Direct origination and other represented 92% of the total portfolio. We expect this percentage to increase next quarter given the Merck's paydown. At the end of June, the non-directly originated loans acquired from the closed-end funds represented just 2% of the portfolio. Merck's accounted for 5.6 of the total portfolio at the end of June, but today it's closer to 2.8%, given the post-quarter end pay down. All of the figures above are on a fair value basis. Specific to the direct origination portfolio, at the end of June, 99% was first lien and 90% was backed by financial sponsors, both on a fair value basis. The average funded position was $13.1 million. The median EBITDA was approximately $50 million. Approximately 96% had one or more financial covenants on a cost basis. Covenant quality is a key point of differentiation for the core middle market, as substantially all of our deals have at least one covenant compared to larger deals, which are generally without covenants. The weighted average yield at cost of our direct origination portfolio was 10.5% on average for the June quarter, down from 10.7% for the March quarter. At the end of June, the weighted average spread on the directly originated corporate lending portfolio was 568 basis points, down one basis point compared to the end of March. Since the initial tariff announcements earlier this year, MidCap has been analyzing the potential impacts across the entire portfolio on a company-by-company basis. This review has been refined and is ongoing. As a reminder, we primarily lend U.S. service-oriented businesses. and we are underweight businesses that are heavily dependent on imports and exports. Our underwriting process always includes a downside scenario, and we have supplemented our underwriting process in response to the tariffs. MidCap Financial leads and serves as an administrative agent on the vast majority of MFIC's direct lending deals. At the end of June, MidCap Financial, or Apollo, was the agent on 72% of MFIC's direct lending portfolio at fair value. This leadership position allows us to be in active dialogue with our borrowers and have enhanced information flow, which is particularly valuable during volatile periods. Being agent allows us to detect and address any issues early. Our underwriting on mid-cap financial source loans has proven to be sound. Based on data since mid-2016, which is the approximate date upon which we began utilizing our co-investment order, our annualized net realized and unrealized loss rates is approximately six basis points on loans sourced by MidCap Financial. We think this performance data shows how well the strategy has performed. We observed a slight increase in net leverage, or debt to EBITDA, of our borrowers. The weighted average net leverage was 5.32 times at the end of June, up from 5.25 times at the end of March. The increase was due to a small number of existing positions, partially offset by new investment. As mentioned, new commitments made during the quarter had a net leverage of 4.0 times. At the end of June, the weighted average interest coverage ratio is 2.1 times, flat compared to last quarter. These metrics are generally based on financial information as of the end of March 2025. We believe the stable level of revolver utilization is an additional sign of the health of our portfolio companies. At the end of June, the percentage of our leveraged lending revolver commitments that were drawn was roughly unchanged from the prior quarter. we believe a steady revolver utilization rate is an indicator of financial stability. During the quarter, we restored three positions to accrual status, following the successful restructuring in two of these cases, highlighting our ability to navigate credit issues. We also placed three first lien positions on non-accrual status due to company-specific challenges, new era, amplity, and compass health. Investments on non-accrual status represented 2% of the portfolio at fair value. up from 0.9% last quarter, and the number of companies on non-accrual decreased by one. Thick income represented 6.4% of total investment income for the June quarter. With that, I will now turn the call over to Kenny to discuss our financial results in detail.

Thank you, Ted, and good morning, everyone. I'm honored to join MFIC as Chief Financial Officer and excited to be part of the team and look forward to connecting with each of you soon. Since stepping into the role a little over a month ago, I've been working closely with Greg to ensure a seamless transition. I will now review our second quarter results in greater detail. Total investment income for the June quarter was approximately $81.3 million, up $2.6 million, or 3.2% compared to the prior quarter. The increase was primarily attributable to higher interest income due to growth in the portfolio, as well as higher prepayment income, partially offset by a decline in fee income, and the impact from an increase in investments on non-accrual status. Pre-payment income was approximately $1.2 million, up from $0.6 million last quarter. Fee income was approximately $220,000, down from approximately $330,000 last quarter. Dividend income was approximately $200,000, essentially flat quarter of the The weighted average yield at cost of our directly originated lending portfolio was 10.5% on average for the June quarter, down from 10.7% last quarter. Net expenses for the quarter were $44.9 million, up from $44.4 million last quarter. This increase was driven by higher interest expenses and G&A expenses, partially offset by a lower incentive fee. Interest expense rose due to a higher amount of debt outstanding due to growth in the portfolio. Other G&A expenses devoted $1.6 million for the quarter, up from $1.2 million in the March quarter. As discussed on the last quarter's call, during the March quarter, we received a reimbursement from Merck's for certain expenses previously incurred by MFIC on Merck's behalf. This was recorded as a contra expense. As mentioned on last quarter's call, we expect other G&A to average around $1.6 million per quarter. This amount is in addition to administrative service expenses, which are around $1 million per quarter. MFIC's stated incentive fee rate is 17.5% and is subject to a total return hurdle with a rolling 12-quarter lookback. Given the total return hurdle feature and the net loss incurred during the lookback period, MFIC's incentive fee for the June quarter was $3.9 million, or 9.6% of pre-incentive fee NII. For the June quarter, net investment income per share was $0.39, and gap earning per share, or net income per share, was $0.19. These results correspond to an annualized ROE based on net investment income of 10.5%, and an annualized ROE based on net income of 5.2%. Results for the quarter, including net loss of approximately $18.3 million, or 20 cents per share, primarily due to losses on a handful of investments, as previously mentioned. Turning to the balance sheet, at the end of June, the portfolio had a fair value of $3.33 billion. Total principal debt outstanding of $2.05 billion, and total net assets stood at $1.3 billion, or 14.75 cents per share. net leverage at the end of the quarter was 1.44 times. Average net leverage for the June quarter was 1.35 times, reflecting the timing of investment activity. This compares to average net leverage of 1.21 times for the March quarter. Given our visibility to the anticipated MRX paydown, we adjusted our pace of deployment in the June quarter accordingly. On a pro forma basis, including the approximate $90 million net repayment for MRX, Net leverage at the end of June would have been around 1.37 times. Gross fundings for the quarter, excluding revolvers, totaled $254 million. Net fundings for the quarter were $144 million. Turning to our capital base, we currently intend to reprice and upsize our first CLO, MFIC Bethesda CLO-1, in the fall. CLO has spread and tightened considerably since our first CLO priced in September 2023. Of course, the timing and pricing of any future CLO transaction is subject to prevailing market conditions. Lastly, we were pleased that in June, Kroll affirmed MFIC's investment grade rating of BBB- with a positive outlook. This concludes our prepared remarks. Operator, please open the call to questions.

Thank you. At this time, if you would like to ask a question, please press the star 1 on your telephone keypad. You may remove yourself from the queue at any time by pressing star 2. Once again, that is star one to ask a question. We'll take our first question from Finian O'Shea with Wells Fargo Securities. Please go ahead.

Hey, everyone. Good morning. Congrats on Merck's and all the new appointments. I actually wanted to hit on Merck's again. There was a lot there. Is the pro forma going to be part, I think you said 40%. a servicing business and the remaining equity, does that mean the remaining kind of looks like what it does now, a levered aircraft business and then part of servicing business and that will stay in place as a strategic, I guess, portfolio position?

So thanks, Finn. So that's generally correct. Let me modify how you described it. The 40% is correct, is that of the remaining roughly $95 million of exposure, 40% is in the servicing business. The slight modification I would make to how you described it It is not a strategic investment. We are not taking on any more servicing contracts there. And the 40% represents previously signed contracts and, in particular, servicing of our drawdown commingled fund navigator. And those are revenues that will come in over time. And so it's not a strategic business, but is related to the servicing of planes. So there's no balance sheet risk for Merck's. Merck's will be paid a portion of the rent that is paid to Navigator. And then when we sell transactions, Merck's will benefit from a payment with regards to the amount of the planes that are sold. So not strategic, but it is related to the servicing.

And again, does that run off with the current Navigator Fund family, or is that complex growing, and is that service business expected to grow?

No, so good question and helpful clarification. That will run off over time as we sell the remaining planes that are in Navigator. That is not expected to grow.

Okay, thanks. Just a follow-up on co-investment. It looks like you did sort of back-to-back orders here. I know there's some regulatory relief, but seeing what that sort of plain English means here, for mid-cap and if more Apollo funds are straightforwardly entitled to mid-cap origination?

So generally speaking, the movement in the order has been positive. There were COVID-related modifications that were enhanced, some of which became permanent. And generally speaking, The direction has been one where it has allowed for greater flexibility. In terms of the mid-cap origination, the availability of the origination is the same as it always was. modification in the rules and the clarification, frankly, of some of the rules has generally meant a greater flexibility for balance sheets across Apollo to participate in transactions. You know, for instance, to get a little bit more granular, you know, some of the new rulemaking has enabled funds to come in, even if they didn't participate in the original transaction. And so generally speaking, given more flexibility. But, you know, in principle, the dynamic is the same as it was, wherein the origination is available more broadly. These rules just make, just add to the flexibility.

Okay. All for me. Thanks so much.

Thank you. And next we'll go to Erin Sykovonek with Truesta. Please go ahead.

Thanks. I was hoping you could talk a little bit about investing expectations for the second half of the year, you know, what you're seeing, how busy the pipeline is, et cetera.

Yeah. Oh, go ahead. Sorry. Oh, yeah. Thanks for the question, Aaron. You know, just taking it from the beginning of the year, there were high expectations, you know, for a pretty robust M&A market. And then in the first half, what kind of played out was uncertainty around tariffs and what type of legislation was going to get passed. Uh, you know, I would say, you know, by the end of April, we started to see a little more clarity around all those things and kind of market sentiment, you know, started to get a little more bullish. If you look at most major markets, you know, they're, they're up for the year. Um, And what we've seen over the last several months is that the M&A pipeline has continued to build. It's not always one-to-one in terms of the deals that we're screening and taking to investment committee that actually get transacted, but just the number of deals that we're seeing. Sponsors are very active. There's been reports out there about how the sponsors have a longer duration of their portfolio. They've been holding on to companies longer. There's still a lot of dry powder that needs to go to work. There's a lot of liquidity in the private credit markets. And so we see all of that coming together to be a pretty active second half. And to the extent that that doesn't play out for whatever reason, with the power of incumbency that we have, you know, we think there'll be plenty of activities to deploy. You know, we've talked about in the past, you know, MidCap has a very large origination business and MFIC only needs a small percentage of that to meet its quarterly and annual origination needs. And so, you know, within the broader market, but also within, you know, the MidCap and Apollo ecosystem, we see plenty of activity and opportunities to deploy. Okay.

Great. I appreciate that. And then the other question was around leverage. It ticked up this quarter to 1.44 net, and I just want to know where you're expecting that to trend, and is that a bit higher than what you like, or is that in the same ballpark that you're okay with?

Yeah, I mean, I think in terms – let's start with new deployments, right? We're deploying – you know, at four times, you know, four to four and a half times. You know, it was four times this quarter, it was 4.2 times last quarter. And so, you know, in that range is where the market is and where we like to be deploying. Like we're very comfortable at that leverage level on new deployments. A lot of the deals that we do are, you know, kind of middle market strategies and the borrowers are acquisitive. And so you'll see sponsors, you know, purchase something at four times and, Their intent and our expectation is that as they do these add-on transactions, there will be periods of time where these companies do lever up to make acquisitions and then will ultimately begin to de-lever again over time. So we do see that kind of dynamic profile. And in terms of the weighted average numbers that we cite on the overall portfolio, we're comfortable there. And then at the fund level, the net leverage ratio, you know, at 1.43 times, we knew that there was a Merck's transaction coming. And so we were deploying, you know, ahead of that so that we could take advantage of good opportunities in the markets.

And I think to Ted's point, if I could add to that, Aaron, quickly, you know, we assigned a non-zero probability of getting the Merck transaction done. So, we came in a little hot for, you know, the avoidance of doubt. It is our intention to operate in and around the bottom end of our range. And you should expect us to be going, you expect us to do that going forward. And then importantly, as we weigh the back half of the year, you know, we're very hopeful, as Ted alluded to, that we will see the pickup in M&A and that will create some new credit creation opportunities and create a little bit more resiliency and stability to spreads. But we, as we always are, will be very deliberate and take account of the risk and what the market is showing us in terms of opportunities as we redeploy the Merck's proceeds that we received.

Got it. Okay. Thanks very much. Appreciate it.

Thank you. Our next question will come from Kenneth Lee with RBC Capital Markets. Please go ahead.

Hey, good morning, and thanks for taking my question. Just one on Merck's. And to clarify, it sounds like after all the announced sales transactions, there's going to be four aircraft remaining in addition to the services platform. Is the four aircraft remaining to one of the two securizations you had left? Or I just want to clarify, you know, how many of the securizations will be left to wind down? Thanks.

So, thanks, Ken. At this juncture, the securizations have been completely paid off. And so these are four planes that we own on balance sheet at Merck's without any leverage.

Okay, great. And then just another point here, in terms of the insurer payments at this point, is there anything remaining there?

Thanks, Ken. Good question. And without going into excruciating detail, the dynamics of the court process in the U.K. are such that the court fines with respect to the insurance claims And then there's a subsequent trial that is needed to adjudicate the interest, the cost to carry, if you will, as well as the recovery of legal. And as is often the case in legal processes, irrespective of whether you're in the U.S. or the U.K., there are settlements in advance of trials or one can settle at any given time. And so we have conservatively estimated what those remaining proceeds will be. But at this juncture, given that we have settled on the primary claims and we've settled a portion of those auxiliary claims, if you will, forgive the term, it would only be expected to be relatively modest. in total size. The vast majority of our claims and potential inflows from our Russia exposures are largely already received.

Gotcha. Gotcha. Great. And just one follow-up, if I may, just on the new non-accruals in the quarter there. Any commonalities that you're seeing there, and how many were either indirectly or directly related to tariffs, perhaps? Thanks.

Yeah, you know, I think in terms of, you know, themes, you know, there are different types of businesses. you know, they've all seen some level of cost pressure, you know, across the board, you know, whether that's, you know, interest rates, labor, et cetera. But as with most restructuring transactions, there's no one single factor. You know, there's kind of a culmination of various levers that come together and result in restructuring. You know, and I would say one thing, you know, that we're kind of watching are just – balance sheets that were constructed, you know, in a lower interest rate environment and, you know, companies that where you have kind of good company, bad balance sheet situations. And that was a driver, you know, in particular of, you know, probably our biggest one.

Gotcha. Very helpful there. Thanks again.

Our next question comes from Robert Dodd with Raymond James. Please go ahead.

Hi, guys. Just on the spread environment and the opportunities going into the rest of the year, I think it was Ted said, right, the weighted average portfolio yield as presentation was 568. The new deployments, excluding a couple of outliers, were 526. So there's about a 40 basis point gap between what's coming on versus what's in the portfolio. So, you know, should we continue to expect spread compression in the portfolio, even if deployment spreads remain stable, should we expect spread compression? Or is that kind of a mixed thing, right? Because it's not necessarily like for like on the type of assets that have a 575 spread versus the type of assets that are, you know, coming on a 525 spread. I mean, what's kind of the outlook there?

Yeah, sure. Thanks, Robert. So, part of the math is extraordinarily easy, right? If you look at our existing book, which itself was constructed over the last several years, and in particular, in rather attractive vintages from a spread perspective of 22 and 23, the existing portfolio is at 568. The primary market is as low fives and frankly is dipping into the force in in many cases and if you were to get more granular with our uh spread uh for the risk that we put on the books in this particular quarter we benefited from the fact that um you know the power of incumbency wherein we were in generally speaking where we were deploying into existing portfolio companies it was a little bit higher than where the primary market was. And so very simply, if we're at 568 and the primary market is wrapped around five or even dipping into the fours, that would be expected to come down. What we have seen, Robert, is that the pricing activity has slowed down, in part due to the fact that a lot of it has already been done. And then when we look at the back half of the year to add some maybe dynamism to how we're thinking about it or how it could play out, I'll emphasize, and though the market has underperformed relative to expectations rather consistently in producing new M&A, new credit creation opportunities, but we're hopeful that that will come to bear in the back half of the year and add some stability to to the spread environment. You know, I think the emphasis is, you know, particularly as the liabilities have gotten to a better place. I'll draw your attention to what we were able to do in CLO Bethesda 2 earlier this year and the prospects for looking at the spread that we have on Bethesda 1. You know, L500 or S500 is still a level at which we can make good money, enhanced by the remarking of our liabilities to maintain them or otherwise to mitigate the effects of the spread environment. So we would expect it to come down, but generally speaking, And in part due to better execution on liabilities, better cost of capital, it's still a level at which we believe, particularly in light of where base rates are, where we can create good risk-adjusted return and ultimately returns for our shareholders.

Got it. Got it. Thank you. I mean, kind of tied to, obviously, I mean, leverage, you know, for new deployments was down to four this quarter, which I think is, you know, more than a turn below your overall portfolio average. And I realize, like you talked about, you know, the M&A pipeline is starting to rebound. But, I mean, do you think the leverage ask is going to increase you know, call it the second half of this year or into next year, because obviously four turns for what you're putting on is considerably lower than the portfolio average. Again, I mean, it's kind of the spread per unit of risk. I mean, what are your thoughts there in terms of if the market activity is going to rebound, is it going to be at a higher leverage ask from sponsors?

um and and what are your thoughts on like the pricing you do that for so to speak yeah so as we and and as we get more into the prognosticating i'll make the necessary caveats that you know a lot of a lot of things could it could ultimately influence but you're notwithstanding i think robert i think particularly at this moment in time where we've seen a little bit more clarity where the tariff uncertainty is moderated, there's more clarity coming out of the legislation and the tax bill, and then the need to deploy this M&A capital. It's generally been a borrower-friendly market, which itself is also influenced by the technical, which we're all very aware of, is in a muted M&A environment and significant supply of capital. has resulted in tighter spreads and also generally borrower-friendly terms. And so when we look at the back half of the year and into 26, frankly, the balance there or how we're looking at it is we likely will see borrower-friendly requests come in, and you could see that leverage level tick up. which, of course, will be balanced by the first. But my answer to your first question is we're very hopeful that M&A volumes will go up, which will help to alleviate that technical to some extent. And then the final point I would make, Robert, is generally speaking, when we look at our franchise relative to some of our peers, we generally will over-index into true first lean or stretch senior and are generally of the variety across the continuum of private credit players. One, to accept lower spreads, but for lower leverage. But that said, and to circle back to specific your question, I think four was maybe a little bit light in any event. And generally speaking, particularly if we don't see that M&A volumes materially. And frankly, even if we do, given the supply of capital and what sponsors need to make the math work for their IRRs, it wouldn't be surprising to see a tick up in leverage in the back half of the year.

Got it. Got it. Thank you for that. And one, just final sort of clarification. To the point on the net leverage at the end of the quarter, I mean, you basically already redeployed the capital you're getting back from Merck at the end of Q2. So there's not going to be a lag of you getting a chunk of cash coming in. It's already been redeployed into earning assets.

Is that right? Yes. And sorry, not to give you a longer answer here. That's generally correct. I would caution this is There's a lot of things that you're managing going into quarter end, and coming out at 144 was a little hot, but not substantially so. And that number, particularly when things fund, can ebb and flow and is very much within the target. But, yes, the math is we would, as our guidance says, that we've repeated in the past, and I repeated earlier in the call, generally want to be at the bottom end of the range. And so, yes, part of the $90 million has already been deployed, but would caution that in any given quarter, you know, 144 is not, it's not surprising to see that number sort of, that little bit of volatility in that number, a quarter end, given that we're managing very disparate processes and when things fund can vacillate a bit. And there's no reason to try to be too prescriptive or too specific in how we manage it.

Yeah, and Robert, one just quick data point would be, you know, if you include the $90 million net repayment for Merck's net leverage at the end of June would have been 1.37 times. So, to Tanner's point, you know, kind of 1.4 plus or minus, you know, is where we're trying to be.

Yeah, got it. Thank you.

Thank you. And we'll go next to Melissa Waddell with J.P. Morgan. Please go ahead.

Good morning. Thanks for taking my questions. A lot of them have been asked already and answered, but wanted to touch base quickly on Repayment expectations, obviously outside of Merck, he's done a great job detailing, um, you know, what you are expecting in the third quarter. And then also later this year into early 26 beyond Merck. Are you expecting, you know, if you do get that pickup and MNA activity, are you expecting something sort of commensurate in the repayment side? Or is there anything else you have visibility to in the near term, um, elsewhere in the portfolio?

Yeah, I wouldn't say that there are, you know, major specific deals that we have earmarked for repayment. We know that there are a handful of companies that are in processes, you know, via our dialogue with the sponsor. You know, most of our portfolio kind of falls below the threshold of term loan fees. So getting taken out by that level of financing is quite episodic, you know, and it's pretty rare. And then in terms of M&A, I mean, yes, if M&A picks up, we're going to have opportunities to deploy, and there will be deals that go away from us. But on a net-net basis, we believe we can continue to stay deployed at our target leverage levels.

Okay. Thanks for that. And then as I think about the, you know, rough math you gave in terms of expectations around additional earnings potential as you rotate that Merck's investment of about $0.06 a share annually in NII, are you thinking of that as being essentially an offset to any base rate pressure or declining base rates that we might see? In terms of what that means for dividend coverage, are you feeling good about that $0.38 and fully covering that through NII, given these portfolio developments? Thanks.

Yeah, sure. I would modify what you said, Melissa. We don't think about it specifically, but you obviously identified really important drivers, right? All things being equal. base rates going down pressures dividends. And one of the things that we have in the toolbox, so to speak, or one of the dynamics which we can point to is the redeployment of Merck. So it's not, we don't, again, there are a lot of factors there. And then to answer your specific question, obviously, And hopefully this is apparent. A lot of it depends on how steep the base rate cuts are. We feel good given the given trajectory, particularly in light of the sixth sense that we calculate to be the accretion from the redeployment of Merck's. But I think, you know, clearly there's a level. And if cuts prove to be significantly higher, you know, obviously the calculus is different and the math is different. But given the current trajectory, yes, we do feel good about where we sit with respect to the dividend.

Okay. Thanks for that. And I guess a clarifying point, too. The six cents per share is just from this first block of repayment from Merck. Is that right?

That's correct.

Okay. Thank you very much.

Again, as a reminder, ladies and gentlemen, if you would like to ask a question, that is star one on your telephone keypad. We'll go next to Chris Gastelou with CJ Advisors. Please go ahead.

Yeah, hi. Just a clarification on the impact of the Merck's transactions. The 10Q says they should result in a positive impact to NAV in the high single-digit-per-share range. By high single-digit-per-share, do you mean $0.06 to $0.09 or something else?

Yes, $0.06 to $0.09.

That's it. Thank you.

Thank you. And that does conclude our question and answer session. I'd like to now turn the call back to management for any final or closing remarks.

Thank you, operator. Thank you, everyone, for listening to today's call. On behalf of the entire team, we thank you for your time today. Please feel free to reach out to us if you have any other questions. Have a good day.

Thank you. And ladies and gentlemen, that does conclude today's conference. We appreciate your participation. Have a wonderful day.